AstraZeneca cited a surplus of updated vaccines leading to a decline in demand for Vaxzevria, which resulted in its discontinuation worldwide.
Although Vaxzevria was crucial early in the pandemic and saved millions of lives, it became less effective against newer variants like omicron.
The Oxford-AstraZeneca vaccine was rapidly developed in 2020 and initially effective against ancestral variants, but faced decreasing usage in several countries prior to its withdrawal.
Governments like those in the UK, Germany, and Australia had already halted the use of AstraZeneca's vaccine before its official withdrawal from the market.
[
add
]
[
|
|
...
]